Deal watch: IL-2 focus switches to stimulating Tregs

Nature Reviews Drug Discovery 16, 595 (2017). doi:10.1038/nrd.2017.171 Author: Megan Cully Recombinant interleukin-2 (IL-2) has been used since the early 1990s for the treatment of renal cell carcinoma and melanoma, as high-dose IL-2 has immune-stimulating properties. A spate of deals in 2017 — including Eli Lilly's acquisition of co-development rights to Nektar's NKTR-358, the acquisition
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research